Hem › Multipelt myelom › North Carolina › Durham
Kliniska studier för Multipelt myelom i Durham, NC
37 studier för Multipelt myelom söker deltagare vid platser i och runt Durham (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekryterarFas 3
- Research Site, Chapel Hill · 10 mi bort
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RekryterarFas 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi bort
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekryterarFas 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
RekryterarFas 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi bort
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekryterarFas 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi bort
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekryterarFas 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi bort
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RekryterarFas 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi bort
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
RekryterarFas 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi bort
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RekryterarFas 1/2
- GSK Investigational Site, Chapel Hill · 10 mi bort
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekryterarFas 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekryterarFas 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekryterarFas 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi bort
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Rekryterar
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi bort
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RekryterarFas 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RekryterarFas 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi bort
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekryterarFas 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi bort
Selinexor and Backbone Treatments of Multiple Myeloma Patients
RekryterarFas 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi bort
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RekryterarFas 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi bort
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
RekryterarFas 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi bort
Registry of Older Patients With Cancer
RekryterarObservationsstudie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi bort
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekryterarFas 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RekryterarFas 2
- University of North Carolina, Chapel Hill · 10 mi bort
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RekryterarFas 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi bort
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RekryterarFas 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi bort
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RekryterarFas 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi bort
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekryterarFas 1
- University of North Carolina, Chapel Hill · 10 mi bort
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RekryterarFas 1
- University of North Carolina, Chapel Hill · 10 mi bort
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekryterarFas 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi bort
Registry for Adults With Plasma Cell Disorders (PCD's)
RekryterarObservationsstudie
- North Carolina Cancer Hospital, Chapel Hill · 10 mi bort
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RekryterarObservationsstudie
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi bort
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekryterarFas 1
- Duke University Health System (DUHS), Durham
Multipelt myelom-studier i andra städer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
- Seattle, WA22 studier
Andra studier i Durham
- Bröstcancer63 studier
- Cancer (alla typer)58 studier
- Icke-småcellig lungcancer39 studier
- Metastaserande cancer33 studier
- Akut myeloid leukemi33 studier
- Lungcancer32 studier
- Prostatacancer32 studier
- Kolorektal cancer28 studier
- Kronisk lymfatisk leukemi27 studier
- Äggstockscancer27 studier
- Hjärtsvikt26 studier
- Bukspottkörtelcancer24 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.